Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 13/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22226389 | 0.83 | P2RY12 (0.40) | CYP11B2NPC1RAB9A | |
| SCHEMBL10053887 | 0.83 | CYP11B2 (0.45) | CYP11B2ESR2NR1H2 | |
| SCHEMBL2964825 | 0.82 | CYP11B2 (0.42) | CYP11B2ESR2NR1H2 | |
| SCHEMBL471037 | 0.81 | CYP11B2 (0.40) | CYP11B2ESR2NR1H2GPR119 | |
| SCHEMBL2959088 | 0.80 | CYP11B2 (0.41) | CYP11B2ESR2NR1H2 | |
| SCHEMBL12043855 | 0.79 | CYP11B2 (0.44) | CYP11B2ESR2NR1H2GPR119 | |
| SCHEMBL20364359 | 0.78 | ESR2 (0.50) | ESR2NR1H2GPR119 | |
| SCHEMBL13691905 | 0.77 | DHODH (0.53) | ESR2DHODHMPONPC1RAB9A | |
| SCHEMBL22226388 | 0.77 | CYP11B2 (0.45) | CYP11B2 | |
| SCHEMBL30513283 | 0.76 | CYP11B2 (0.41) | CYP11B2ESR2NR1H2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901126-B2 | Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases | ASTELLAS PHARMA INC. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-8901126-B2 | Substituted imidazo[1,5-A]quinoxalin-4-ones are useful for preventing or treating storage dysfunction, voiding dysfunction and bladder/urethral diseases | ASTELLAS PHARMA INC. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130296329-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296329-A1 | QUINOXALINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| WO-2012033101-A1 | QUINOXALINE COMPOUND | アステラス製薬株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296329-A1 | QUINOXALINE COMPOUND | PDE9A, PDE5A, PDE2A | CYP11B2 3623/4885ESR2 4743/4885NR1H2 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.